But @sarge17 we have been told constantly by JF and Starpharma ( and @antibotter) that we didn't need phase 3 trials .... we were a shoe in for the FDA Section 505 (b) [2] application for our DEP in house trialed drugs ..... supposedly so easy for any of the big pharmas to do and yet they're still not interested ? lol
Post #:66584800
As previously stated by Starpharma in announcements over the years, once phase 2 of the three in house trials have been completed and licensed out to a tier 1 pharma, a 505(b)(2) application may be made to the regulatory authorities to bypass phase 3 clinical trials and bring straight to market our Dep Docetaxel, Dep Cabazitaxel, and Dep Irinotecan
Post #:66588151
Based on the a 505(b)(2) application scenario being successful, tier 1 pharma would spend absolutely nothing on Phase 3 trials.
- Forums
- ASX - By Stock
- DEP Phase 3 trials no certainty
But @sarge17 we have been told constantly by JF and Starpharma (...
-
- There are more pages in this discussion • 7 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add SPL (ASX) to my watchlist
(20min delay)
|
|||||
Last
9.5¢ |
Change
-0.002(2.06%) |
Mkt cap ! $39.64M |
Open | High | Low | Value | Volume |
9.7¢ | 9.8¢ | 9.5¢ | $10.25K | 106.1K |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
3 | 18324 | 9.5¢ |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
9.8¢ | 159206 | 3 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
3 | 18324 | 0.095 |
3 | 160000 | 0.094 |
3 | 109659 | 0.093 |
2 | 134306 | 0.092 |
4 | 92564 | 0.090 |
Price($) | Vol. | No. |
---|---|---|
0.098 | 159206 | 3 |
0.100 | 4000 | 1 |
0.105 | 174620 | 5 |
0.110 | 148286 | 8 |
0.115 | 103400 | 3 |
Last trade - 16.10pm 14/10/2024 (20 minute delay) ? |
Featured News
SPL (ASX) Chart |
The Watchlist
I88
INFINI RESOURCES LIMITED
Charles Armstrong, Managing Director & CEO
Charles Armstrong
Managing Director & CEO
SPONSORED BY The Market Online